Core Problem Statement

The total unavailability of reliable, affordable, and minimally invasive diagnostic tests for Parkinson's disease causes late-stage detection and missed clinical windows for early therapeutic intervention.

Solution Overview

A patented blood-based diagnostic platform utilizing mutant-based amyloid amplification and engineered alpha-synuclein seeds for high-precision biomarker detection. The system provides PCR-like amplification mechanics for early neurodegenerative tracking.

Strategic Engagement Opportunities

AmyScan's patented assay and multicentric clinical data model position it as a strong translational research and biomarker development partner for neurodegeneration institutes, global pharmaceutical majors, and diagnostic networks.